AMERICAN SOCIETY FOR CLINICAL PATHOLOGY

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Stark Self-Referral Reform; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments ; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; federal oversight of laboratory tests including laboratory developed testing services; immigration

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform; the RESULTS Act

Physician, clinical laboratory professional, and allied health workforce issues, Federal Funding for Education, Student loan Repayment/Forgiveness, and Related Workforce Development; Workforce Reinvestment Act; Federal Healthcare Workforce Issues; Appropriations for Federal Agencies; Clinical Laboratory Improvement Amendments; COVID-19 Response and Laboratory Test Capacity; immigration issues impacting laboratory workforce

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform; the RESULTS Act